Italia markets closed

Illumina, Inc. (ILMN)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a portafoglio
331,96+7,60 (+2,34%)
Alla chiusura: 04:00PM EST
332,00 +0,04 (+0,01%)
Dopo ore: 07:06PM EST

Illumina, Inc.

5200 Illumina Way
San Diego, CA 92122
United States
858 202 4500
https://www.illumina.com

Settore/iHealthcare
SettoreDiagnostics & Research
Impiegati a tempo pieno7.800

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Francis A. deSouzaCEO & DirectorN/DN/D1972
Mr. Sam A. SamadChief Financial Officer716,04kN/D1970
Dr. Alexander Aravanis M.D., Ph.D.CTO & Head of Research and Product Devel.416,48kN/D1976
Ms. Susan H. TousiChief Commercial Officer655,31kN/D1969
Stephanie CamposPresN/DN/DN/D
Mr. Kevin Carl PegelsChief of Global OperationsN/DN/DN/D
Mr. Jose A. Torres Jr.Chief Accounting Officer & VPN/DN/D1975
Mr. Steve PhillpottSr. VP & Chief Information OfficerN/DN/DN/D
Ms. Sallilyn SchwartzVP of Investor RelationsN/DN/DN/D
Mr. Charles E. DadswellSr. VP, Gen. Counsel & Sec.N/DN/D1959
Gli importi risalgono al giorno 31 dicembre 2020 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has collaboration agreements with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer; LetsGetChecked to track COVID-19 variants in California; and Merck & Co., Inc. to develop and commercialize tests that identify genetic mutations used in the assessment of homologous recombination deficiency. The company was incorporated in 1998 and is headquartered in San Diego, California.

Governance aziendale

L'ISS Governance QualityScore di Illumina, Inc. al 26 settembre 2021 è 6. I criteri di valutazione fondamentali sono revisione: 3; Consiglio di Amministrazione: 1; diritti degli azionisti: 6; retribuzione: 9.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.